ADC Therapeutics S.A. (ADCT) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ADCT Revenue Growth
Revenue Breakdown (FY 2025)
ADCT's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ADCT Revenue Analysis (2017–2025)
As of May 8, 2026, ADC Therapeutics S.A. (ADCT) generated trailing twelve-month (TTM) revenue of $79.2 million, reflecting moderate decline in growth of -9.5% year-over-year. The most recent quarter (Q1 2026) recorded $20.9 million in revenue, down 9.6% sequentially.
Looking at the longer-term picture, ADCT's historical revenue data shows a 3-year CAGR of -27.1%. The company achieved its highest annual revenue of $209.9 million in 2022.
Revenue diversification analysis shows ADCT's business is primarily driven by Product (90%), License Revenues (6%), and Royalty Revenue (3%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RCUS (+67.4% YoY), MGNX (+0.8% YoY), and ABBV (+8.6% YoY), ADCT has underperformed the peer group in terms of revenue growth. Compare ADCT vs RCUS →
ADCT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ADCTCurrent | $79M | -9.5% | - | -133.2% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 MGNX | $150M | +0.8% | +8.9% | -48.7% | |
 ABBV | $61.2B | +8.6% | +6.0% | 32.8% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% | |
 AIXI | $70M | +16.7% | - | -18.3% |
ADCT Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $81.4M | +14.9% | $73.7M | 90.6% | $-108,379,000 | -133.2% |
| 2024 | $70.8M | +1.8% | $64.9M | 91.6% | $-130,654,000 | -184.4% |
| 2023 | $69.6M | -66.9% | $67.0M | 96.4% | $-165,986,000 | -238.6% |
| 2022 | $209.9M | +518.9% | $206.6M | 98.4% | $-123,344,000 | -58.8% |
| 2021 | $33.9M | - | $32.5M | 95.9% | $-261,720,000 | -771.6% |
| 2020 | $0 | -100.0% | $-141,816,000 | - | $-219,263,000 | - |
| 2019 | $2.3M | +105.3% | $2.3M | 100.0% | $-119,399,000 | -5102.5% |
| 2018 | $1.1M | -36.8% | $-116,946,000 | -10258.4% | $-125,941,000 | -11047.5% |
| 2017 | $1.8M | - | $-83,727,000 | -4643.8% | $-91,670,000 | -5084.3% |
See ADCT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADCT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ADCT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonADCT — Frequently Asked Questions
Quick answers to the most common questions about buying ADCT stock.
Is ADCT's revenue growth accelerating or slowing?
ADCT revenue declined -9.5% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $79M. This reverses the prior growth trend.
What is ADCT's long-term revenue growth rate?
ADC Therapeutics S.A.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -9.5% is below this long-term average.
How is ADCT's revenue distributed by segment?
ADCT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.